Contributions
Abstract: P359
Type: Poster
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Introduction: With increasingly effective therapies for the treatment of relapsing remitting multiple sclerosis (RRMS), status of “no evidence of disease activity” (NEDA) has become the main goal. Whether EDSS is sensible enough to reflect disease progression has been a topic of discussion.
Objective: The aim of this study was to determine if the timed 25-foot walk (T25FW), the 9-hole peg test (9HPT) or the symbol digit modalities test (SDMT) change the classification of disease activity comparing to EDSS.
Methods: Patients with RRMS were evaluated using the same battery test, in two different moments. Disease activity between the evaluations was revised and patients were classified as “stable” or “unstable” using relapse rate (>1), brain MRI (≥2 Gd-enhancing or new lesions), EDSS (>1 point), T25FW (worsening >20%), 9HPT (worsening >20% in one side) and SDMT (worsening >40%). The Rio Score was calculated and compared to three adapted versions of Rio Score using T25FW, 9HPT and SDMT instead of EDSS.
Results: A total of 144 patients were included in this study: mean age=42±11 years, mean years of education=14±6, mean disease duration=12±7 years; at first evaluation mean EDSS= 2.3±1.8 and 73% under disease modifying treatment (DMT); mean time between evaluations=12±6 months. 74.3% of patients were considered NEDA (Rio score=0) with EDSS, 77.6% with SDMT (p>0.05), 70.2% with 9HPT (p>0.05) and 61.1% with T25FW (p=0.017, corresponding to 25 patients). None of these patients switched DMT because of disease progression. There is no significant difference between patients who maintained NEDA and patients who scored 1 with T25FW, concerning age, disease duration, interval of evaluations and the other tests.
Conclusion: Almost a quarter of patients considered NEDA with EDSS were not stable with T25FW. However, it had no impact on treatment decision. More studies are needed to validate this tool as a marker of disease activity.
Disclosure: Joana Martins: nothing to disclose
Raquel Samões: nothing to disclose
Inês Moreira: nothing to disclose
Andreia Bettencourt: nothing to disclose
Ernestina Santos: nothing to disclose
Ana Martins Silva: nothing to disclose
Abstract: P359
Type: Poster
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Introduction: With increasingly effective therapies for the treatment of relapsing remitting multiple sclerosis (RRMS), status of “no evidence of disease activity” (NEDA) has become the main goal. Whether EDSS is sensible enough to reflect disease progression has been a topic of discussion.
Objective: The aim of this study was to determine if the timed 25-foot walk (T25FW), the 9-hole peg test (9HPT) or the symbol digit modalities test (SDMT) change the classification of disease activity comparing to EDSS.
Methods: Patients with RRMS were evaluated using the same battery test, in two different moments. Disease activity between the evaluations was revised and patients were classified as “stable” or “unstable” using relapse rate (>1), brain MRI (≥2 Gd-enhancing or new lesions), EDSS (>1 point), T25FW (worsening >20%), 9HPT (worsening >20% in one side) and SDMT (worsening >40%). The Rio Score was calculated and compared to three adapted versions of Rio Score using T25FW, 9HPT and SDMT instead of EDSS.
Results: A total of 144 patients were included in this study: mean age=42±11 years, mean years of education=14±6, mean disease duration=12±7 years; at first evaluation mean EDSS= 2.3±1.8 and 73% under disease modifying treatment (DMT); mean time between evaluations=12±6 months. 74.3% of patients were considered NEDA (Rio score=0) with EDSS, 77.6% with SDMT (p>0.05), 70.2% with 9HPT (p>0.05) and 61.1% with T25FW (p=0.017, corresponding to 25 patients). None of these patients switched DMT because of disease progression. There is no significant difference between patients who maintained NEDA and patients who scored 1 with T25FW, concerning age, disease duration, interval of evaluations and the other tests.
Conclusion: Almost a quarter of patients considered NEDA with EDSS were not stable with T25FW. However, it had no impact on treatment decision. More studies are needed to validate this tool as a marker of disease activity.
Disclosure: Joana Martins: nothing to disclose
Raquel Samões: nothing to disclose
Inês Moreira: nothing to disclose
Andreia Bettencourt: nothing to disclose
Ernestina Santos: nothing to disclose
Ana Martins Silva: nothing to disclose